Colgate Announces 1st Quarter 2026 Results

About this update from Cresco Labs, Inc.

.bwalignc { text-align: center; list-style-position: inside } .bwalignl { text-align: left } .bwalignr { text-align: right; list-style-position: inside } .bwblockalignc { margin-left: auto; margin-right: auto } .bwblockalignl { margin-left: 0px; margin-right: auto } .bwcellpmargin { margin-bottom: 0px; margin-top: 0px } .bwdoublebottom { border-bottom: double black 2.25pt } .bwleftsingle { border-left: solid black 1pt } .bwlistdisc { list-style-type: disc } .bwnowrap { white-space: nowrap } .bwpadb3 { padding-bottom: 4px } .bwpadb4 { padding-bottom: 5px } .bwpadl0 { padding-left: 0px } .bwpadl11 { padding-left: 55px } .bwpadl2 { padding-left: 10px } .bwpadl5 { padding-left: 25px } .bwpadl8 { padding-left: 40px } .bwpadr0 { padding-right: 0px } .bwrightsingle { border-right: solid black 1pt } .bwrowaltcolor0 { background-color: #cceeff } .bwrowaltcolor1 { background-color: #d3d3d3 } .bwsinglebottom { border-bottom: solid black 1pt } .bwtablemarginb { margin-bottom: 10px } .bwtopsingle { border-top: solid black 1pt } .bwuline { text-decoration: underline } .bwvertalignb { vertical-align: bottom } .bwvertalignt { vertical-align: top } .bwwidth1 { width: 1% } .bwwidth10 { width: 10% } .bwwidth11 { width: 11% } .bwwidth15 { width: 15% } .bwwidth17 { width: 17% } .bwwidth2 { width: 2% } .bwwidth26 { width: 26% } .bwwidth3 { width: 3% } .bwwidth4 { width: 4% } .bwwidth46 { width: 46% } .bwwidth55 { width: 55% } .bwwidth58 { width: 58% } .bwwidth59 { width: 59% } .bwwidth67 { width: 67% } .bwwidth7 { width: 7% } .bwwidth74 { width: 74% } .bwwidth8 { width: 8% } .bwwidth85 { width: 85% } .bwwidth9 { width: 9% } Colgate-Palmolive Company (NYSE:CL): Net sales increased 8.4%; Organic sales* increased 2.9%, including a 0.6% negative impact from lower private label pet food sales GAAP EPS decreased 6% to $0.80; Base Business EPS* increased 7% to $0.97 GAAP Gross profit margin and Base Business Gross profit margin* decreased 20 basis points to 60.6% Net cash provided by operations was $747 million for the first three months of 2026 The Company’s leadership in toothpaste continued with its global market share at 41.1% year to date The Company’s leadership in manual toothbrushes continued with its global market share at 32.6% year to date The Company maintained its sales and earnings per share guidance and updated its gross profit margin guidance for full year 2026 First Quarter Total Company Results (GAAP) ($ in millions except per share amounts) 2026 2025 Change Net Sales $5,324 $4,911 +8.4% EPS (diluted) $0.80 $0.85 -6% First Quarter Total Company Results (Base Business - Non-GAAP)* 2026 2025 Change Organic Sales Growth +2.9% Base Business EPS (diluted) $0.97 $0.91 +7% *Indicates a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” later in this release for definitions of non-GAAP financial measures and to “Table 5 - Geographic Sales Analysis Percentage Changes” and “Table 6 - Non-GAAP Reconciliations” included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures. Colgate-Palmolive Company (NYSE:CL) today reported results for first quarter 2026. Noel Wallace, Chairman, President and Chief Executive Officer, commented on the Base Business first quarter results, “We delivered a strong start to 2026, with broad-based top and bottom-line growth. Net sales and organic sales grew in every category and in four of five divisions with a nice balance of volume and pricing growth. Gross profit margin increased sequentially versus fourth quarter 2025 and operating profit, net income, earnings per share and free cash flow all increased year over year along with an increase in advertising spending. "These results underscore the resilience of our business model as we are able to execute against our long-term strategy while delivering strong results in a difficult operating environment. While we expect the volatile macroeconomic conditions and slower category growth to continue in 2026, we are aligned behind our 2030 strategy to deliver consistent, compounded earnings per share growth and drive long-term shareholder value.” Separately, building on the Company’s successful implementation of the Strategic Growth and Productivity Program (the “SGPP”) to date, on April 30, 2026, the Company's Board of Directors approved an expansion of the SGPP to continue to align the Company’s operations to drive future growth and support the Company’s 2030 strategy. The Company still expects substantially all of the charges to be incurred by December 31, 2028. As a result of the expansion, cumulative pretax charges related to the SGPP, once all projects are approved and implemented, are now estimated to be $350 million to $550 million, increased from $200 million to $300 million. Cumulative pretax savings are projected to be $200 million to $300 million, annually, once all projects are approved and implemented. Full Year 2026 Guidance Based on current spot rates and including the estimated impact of tariffs announced and finalized as of April 29, 2026: The Company still expects net sales to be up 2% to 6%, including a low-single-digit positive impact from foreign exchange. The Company still expects organic sales growth to be 1% to 4%. This includes the impact from our exit from the private label pet food business. On a GAAP basis, the Company now expects gross profit margin to be down (versus up previously) and still expects advertising to be up on both a dollar basis and as a percentage of net sales and double-digit earnings per share growth. On a non-GAAP (Base Business) basis, the Company now expects gross profit margin to be down (versus up previously) and still expects advertising to be up on both a dollar basis and as a percentage of net sales; it also still expects low to mid-single-digit earnings per share growth. Divisional Performance See attached "Table 5 - Geographic Sales Analysis Percentage Changes" and "Table 4 - Segment Information" for additional information on net sales and operating profit by division. First Quarter Sales Growth By Division (% change 1Q 2026 vs. 1Q 2025 except % of Total Company Sales) % of Total Company Sales Net Sales Organic Sales* As Reported Volume** Pricing FX North America (1) 17% -1.8% -2.2% -3.2% +1.0% +0.4% Latin America 25% +14.8% +5.4% +2.0% +3.4% +9.5% Europe, Middle East & Africa (1) 21% +11.9% +3.5% +2.2% +1.2% +8.5% Asia Pacific (1) 15% +8.9% +5.6% +4.6% +1.0% +3.3% Hill's Pet Nutrition 22% +6.7% +2.1% +0.2% +3.8% +2.7% Total Company 100% +8.4% +2.9% +1.1% +2.2% +5.1% Note: Table may not sum due to rounding. (1) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026. The results of the Europe and Africa/Eurasia (excluding Russia and Belarus) reportable operating segments and the skin health business (previously within the North America reportable operating segment) have been combined in a new Europe, Middle East & Africa reportable operating segment. In conjunction with this realignment, Russia and Belarus, which were previously reported within the Africa/Eurasia reportable operating segment, are now reported within the Asia Pacific reportable operating segment. Recast historical geographic segment information can be found on the Company's website. *Indicates a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” later in this release for definitions of non-GAAP financial measures and to “Table 5 - Geographic Sales Analysis Percentage Changes” included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures. **The impact of the acquisition of the Prime100 pet food business on as reported volume was 1.9% and 0.4% for Hill's Pet Nutrition and Total Company, respectively. First Quarter Operating Profit By Division ($ in millions) 1Q 2026 % Change vs 1Q 2025 % to Net Sales Change in basis points vs 1Q 2025 % to Net Sales North America (1) $141 -28% 15.8% -590 Latin America $401 15% 30.6% +20 Europe, Middle East & Africa (1) $266 20% 23.6% +160 Asia Pacific (1) $222 9% 27.6% -10 Hill's Pet Nutrition $280 8% 23.4% +30 Total Company, As Reported $964 -10% 18.1% -380 Total Company, Base Business* $1,134 4% 21.3% -90 (1) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026. *Indicates a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” later in this release for definitions of non-GAAP financial measures and to “Table 6 - Non-GAAP Reconciliations” included with this release for a reconciliation of these non-GAAP financial measures to the related GAAP measures. Prepared Materials and Webcast Information At approximately 7:00 a.m. ET today, the Company will post its prepared materials regarding first quarter results to the Investor Center section of its website at https://investor.colgatepalmolive.com/events-and-presentations . At 8:00 a.m. ET today, the Company will host a conference call regarding first quarter results. To access this call as a webcast, please go to Colgate-Palmolive’s website at www.colgatepalmolive.com . About Colgate-Palmolive Colgate-Palmolive Company is a caring, innovative growth company that is reimagining a healthier future for all people, their pets and our planet. Focused on Oral Care, Personal Care, Home Care and Pet Nutrition, we sell our products in more than 200 countries and territories under brands such as Colgate, Palmolive, Ajax, Axion, Darlie, elmex, EltaMD, Fabuloso, Filorga, hello, Hill’s Prescription Diet, Hill’s Science Diet, Irish Spring, Lady Speed Stick, meridol, PCA SKIN, Prime100, Protex, Sanex, Softsoap, Sorriso, Soupline, Speed Stick, Suavitel and Tom’s of Maine. We are recognized for our leadership and innovation in promoting sustainability and community wellbeing, including our achievements in decreasing plastic waste and promoting recyclability, saving water and improving children’s oral health through our Colgate Bright Smiles, Bright Futures program, which has reached approximately two billion children and their families since 1991. For more information about Colgate-Palmolive and how we make more smiles, visit www.colgatepalmolive.com . CL-E Market Share Information Management uses market share information as a key indicator to monitor business health and performance. References to market share in this press release are based on a combination of consumption and market share data provided by third-party vendors, primarily Nielsen, and internal estimates. Except as otherwise noted, all market share references represent the percentage of the dollar value of sales of our products, relative to all product sales in the category in the countries in which the Company competes and purchases data (excluding Venezuela from all periods). Market share data is subject to limitations on the availability of up-to-date information. In particular, market share data is currently not generally available for certain retail channels, such as eCommerce and certain club retailers and discounters. The Company measures year-to-date market shares from January 1 of the relevant year through the most recent period for which market share data is available, which typically reflects a lag time of one or two months. The Company believes that the third-party vendors it uses to provide data are reliable, but it has not verified the accuracy or completeness of the data or any assumptions underlying the data. In addition, market share information reported by the Company may be different from market share information reported by other companies due to differences in category definitions, the use of data from different countries, internal estimates and other factors. Cautionary Statement on Forward-Looking Statements This press release and the related prepared materials and webcast may contain forward-looking statements (as that term is defined in the U.S. Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission (SEC) in its rules, regulations and releases) that set forth anticipated results based on management’s current plans and assumptions. Such statements may relate, for example, to sales or volume growth, net selling price increases, organic sales growth, profit or profit margin levels, earnings per share levels, financial goals, category growth rates, the impact of foreign exchange, the impact of developments in global trade relations and tariffs, the impact of geopolitical events and tensions, wars and military conflicts, such as in Ukraine and the Middle East, cost reduction plans (including the Strategic Growth and Productivity Program), tax rates, interest rates, new product introductions, digital capabilities, commercial investment levels, acquisitions, divestitures, share repurchases or legal or tax proceedings, among other matters. These statements are made, except as otherwise noted with respect to tariffs, on the basis of the Company’s views and assumptions as of May 1, 2026. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. Moreover, the Company does not, nor does any other person, assume responsibility for the accuracy and completeness of these statements. The Company cautions investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. For more information about factors that could impact the Company’s business and cause actual results to differ materially from forward-looking statements, investors should refer to the Company’s filings with the SEC (including, but not limited to, the information set forth under the captions “Risk Factors” and “Cautionary Statement on Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings with the SEC). Copies of these filings may be obtained upon request from the Company’s Investor Relations Department or on the Company’s website at www.colgatepalmolive.com . Non-GAAP Financial Measures The following provides definitions and other information regarding the non-GAAP financial measures used in this press release and the related prepared materials and webcast, which may not be the same as or comparable to similar measures presented by other companies: Base Business: Base Business refers to non-GAAP measures of operating results that exclude certain items. Base Business operating results exclude, as applicable, charges related to the Strategic Growth and Productivity Program and the ERISA litigation matter. Organic sales growth: Net sales growth excluding the impact of foreign exchange, acquisitions and divestments. Free cash flow before dividends: Net cash provided by operations less Capital expenditures. This press release and the related prepared materials and webcast discuss Net sales growth (GAAP) and Organic sales growth (non-GAAP). Management believes the organic sales growth measure provides investors and analysts with useful supplemental information regarding the Company’s underlying sales trends by presenting sales growth excluding the external factor of foreign exchange as well as the impact from acquisitions and divestments. See “Geographic Sales Analysis Percentage Changes” for the three months ended March 31, 2026 versus 2025 included with this release for a comparison of Organic sales growth to Net sales growth in accordance with GAAP. Selling, general and administrative expenses, Selling, general and administrative expenses as a percentage of Net sales, Other (income) expense, net, Operating profit, Operating profit margin, Non-service related postretirement costs, Effective income tax rate, Net income attributable to Colgate-Palmolive Company and Diluted earnings per common share are disclosed on both an as reported (GAAP) and Base Business (non-GAAP) basis. These non-GAAP financial measures exclude items that, either by their nature or amount, management would not expect to occur as part of the Company’s normal business on a regular basis, such as restructuring charges, charges for certain litigation and tax matters, acquisition-related costs, gains and losses from certain divestitures and certain other unusual, non-recurring items. Investors and analysts use these financial measures in assessing the Company’s business performance, and management believes that presenting these financial measures on a non-GAAP basis provides them with useful supplemental information to enhance their understanding of the Company’s underlying business performance and trends. These non-GAAP financial measures also enhance the ability to compare period-to-period financial results. See “Non-GAAP Reconciliations” for the three months ended March 31, 2026 and 2025 included with this release for a reconciliation of these financial measures to the related GAAP measures. The Company uses these financial measures internally in its budgeting process, to evaluate segment and overall operating performance and as factors in determining compensation. While the Company believes that these financial measures are useful in evaluating the Company’s underlying business performance and trends, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. As management uses free cash flow before dividends to evaluate the Company’s ability to satisfy current and future obligations, pay dividends, fund future business opportunities and repurchase stock, the Company believes that it provides useful information to investors. Free cash flow before dividends is not a measure of cash available for discretionary expenditures since the Company has certain non-discretionary obligations such as debt service that are not deducted from the measure. See “Condensed Consolidated Statements of Cash Flows” for the three months ended March 31, 2026 and 2025 for a comparison of free cash flow before dividends to Net cash provided by operations as reported in accordance with GAAP. (See attached tables for first quarter results.) Table 1 Colgate-Palmolive Company Condensed Consolidated Statements of Income For the Three Months Ended March 31, 2026 and 2025 (Dollars in Millions Except Per Share Amounts) (Unaudited) 2026 2025 Net sales $ 5,324 $ 4,911 Cost of sales 2,098 1,924 Gross profit 3,226 2,987 Gross profit margin 60.6 % 60.8 % Selling, general and administrative expenses 2,076 1,898 Other (income) expense, net 186 13 Operating profit 964 1,076 Operating profit margin 18.1 % 21.9 % Non-service related postretirement costs 26 72 Interest expense 62 66 Interest income 16 15 Income before income taxes 892 953 Provision for income taxes 211 227 Effective tax rate 23.6 % 23.7 % Net income including noncontrolling interests 681 726 Less: Net income attributable to noncontrolling interests 35 36 Net income attributable to Colgate-Palmolive Company $ 646 $ 690 Earnings per common share Basic $ 0.81 $ 0.85 Diluted $ 0.80 $ 0.85 Supplemental Income Statement Information Average common shares outstanding Basic 802.3 812.0 Diluted 805.1 815.0 Advertising $ 734 $ 668 Table 2 Colgate-Palmolive Company Condensed Consolidated Balance Sheets As of March 31, 2026, December 31, 2025 and March 31, 2025 (Dollars in Millions) (Unaudited) March 31, December 31, March 31, 2026 2025 2025 Cash and cash equivalents $ 1,335 $ 1,288 $ 1,112 Receivables, net 1,889 1,675 1,725 Inventories 2,086 2,032 2,125 Other current assets 772 714 852 Property, plant and equipment, net 4,622 4,660 4,416 Goodwill 3,107 3,122 3,334 Other intangible assets, net 1,521 1,536 1,782 Other assets 1,278 1,303 1,301 Total assets $ 16,610 $ 16,330 $ 16,647 Total debt $ 7,973 $ 7,988 $ 8,269 Other current liabilities 5,898 5,736 5,163 Other non-current liabilities 2,253 2,241 2,482 Total liabilities 16,124 15,965 15,914 Total Colgate-Palmolive Company shareholders’ equity 145 54 363 Noncontrolling interests 341 311 370 Total liabilities and equity $ 16,610 $ 16,330 $ 16,647 Supplemental Balance Sheet Information Debt less cash, cash equivalents and marketable securities (1) $ 6,554 $ 6,593 $ 6,958 Working capital % of sales (5.7 )% (7.0 )% (3.3 )% Note: (1) Marketable securities of $84, $107 and $199 as of March 31, 2026, December 31, 2025 and March 31, 2025, respectively, are included in Other current assets. Table 3 Colgate-Palmolive Company Condensed Consolidated Statements of Cash Flows For the Three Months Ended March 31, 2026 and 2025 (Dollars in Millions) (Unaudited) 2026 2025 Operating Activities Net income including noncontrolling interests $ 681 $ 726 Adjustments to reconcile Net income including noncontrolling interests to Net cash provided by operations: Depreciation and amortization 156 148 ERISA litigation matter — 65 Restructuring and termination benefits, net of cash 165 (7 ) Stock-based compensation expense 40 23 Deferred income taxes (18 ) (24 ) Cash effects of changes in: Receivables (215 ) (174 ) Inventories (41 ) (86 ) Accounts payable and other working capital (11 ) (57 ) Other non-current assets 19 (1 ) Other non-current liabilities (29 ) (13 ) Net cash provided by (used in) operations 747 600 Investing Activities Capital expenditures (138 ) (124 ) Purchases of marketable securities and investments (70 ) (134 ) Proceeds from sale of marketable securities and investments 94 97 Other investing activities (8 ) 2 Net cash provided by (used in) investing activities (122 ) (159 ) Financing Activities Short-term borrowing (repayment) less than 90 days, net 1,138 164 Principal payments on debt (1,082 ) (4 ) Proceeds from issuance of debt — — Dividends paid (417 ) (406 ) Purchases of treasury shares (306 ) (284 ) Proceeds from exercise of stock options 127 40 Other financing activities (23 ) 32 Net cash provided by (used in) financing activities (563 ) (458 ) Effect of exchange rate changes on Cash and cash equivalents (15 ) 33 Net increase (decrease) in Cash and cash equivalents 47 16 Cash and cash equivalents at beginning of the period 1,288 1,096 Cash and cash equivalents at end of the period $ 1,335 $ 1,112 Supplemental Cash Flow Information Free cash flow before dividends (Net cash provided by operations less Capital expenditures) Net cash provided by operations $ 747 $ 600 Less: Capital expenditures (138 ) (124 ) Free cash flow before dividends $ 609 $ 476 Income taxes paid $ 176 $ 139 Interest paid $ 96 $ 109 Table 4 Colgate-Palmolive Company Segment Information For the Three Months Ended March 31, 2026 and 2025 (Dollars in Millions) (Unaudited) Three Months Ended March 31, 2026 2025 Net Sales Oral, Personal and Home Care North America (1) $ 888 $ 904 Latin America 1,313 1,143 Europe, Middle East & Africa (1) 1,126 1,007 Asia Pacific (1) 804 738 Total Oral, Personal and Home Care 4,131 3,792 Pet Nutrition 1,194 1,118 Total Net Sales $ 5,324 $ 4,911 Three Months Ended March 31, 2026 2025 Operating Profit Oral, Personal and Home Care North America (1) $ 141 $ 197 Latin America 401 348 Europe, Middle East & Africa (1) 266 222 Asia Pacific (1) 222 204 Total Oral, Personal and Home Care 1,030 971 Pet Nutrition 280 258 Corporate (2) (346 ) (153 ) Total Operating Profit $ 964 $ 1,076 Tables may not sum due to rounding. Notes: (1) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026. (2) Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets. Corporate Operating profit (loss) for the three months ended March 31, 2026 included charges resulting from the Strategic Growth and Productivity Program of $171. Corporate Operating profit (loss) for the three months ended March 31, 2025 included charges resulting from the ERISA litigation matter of $15. Table 5 Colgate-Palmolive Company Geographic Sales Analysis Percentage Changes For the Three Months Ended March 31, 2026 vs. 2025 (Unaudited) COMPONENTS OF SALES CHANGE Pricing Coupons Sales Consumer & Change Organic As Reported Organic Trade Foreign Region As Reported Sales Change Volume (1) Volume Incentives Exchange Total Company 8.4 % 2.9 % 1.1 % 0.6 % 2.2 % 5.1 % North America (2) (1.8 )% (2.2 )% (3.2 )% (3.2 )% 1.0 % 0.4 % Latin America 14.8 % 5.4 % 2.0 % 2.0 % 3.4 % 9.5 % Europe, Middle East & Africa (2) 11.9 % 3.5 % 2.2 % 2.2 % 1.2 % 8.5 % Asia Pacific (2) 8.9 % 5.6 % 4.6 % 4.6 % 1.0 % 3.3 % Total CP Products 8.9 % 3.1 % 1.3 % 1.3 % 1.8 % 5.9 % Hill’s Pet Nutrition 6.7 % 2.1 % 0.2 % (1.7 )% 3.8 % 2.7 % Emerging Markets (3) 12.9 % 6.2 % 3.5 % 3.5 % 2.7 % 6.7 % Developed Markets 4.9 % 0.2 % (0.9 )% (1.7 )% 1.9 % 3.9 % Table may not sum due to rounding. Notes: (1) The impact of the acquisition of the Prime100 pet food business on as reported volume was 0.4%, 1.9% and 0.8% for Total Company, Hill's Pet Nutrition and Developed Markets, respectively. (2) The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026. (3) Emerging Markets include Latin America, Asia (excluding Japan), Africa, the Middle East and Eastern and Central Europe. Table 6 Colgate-Palmolive Company Non-GAAP Reconciliations For the Three Months Ended March 31, 2026 and 2025 (Dollars in Millions Except Per Share Amounts) (Unaudited) Selling, General and Administrative Expenses 2026 2025 Selling, general and administrative expenses, GAAP $ 2,076 $ 1,898 Strategic Growth and Productivity Program (6 ) — ERISA litigation matter — (15 ) Selling, general and administrative expenses, non-GAAP $ 2,071 $ 1,883 Basis Point Selling, General and Administrative Expenses as a Percentage of Net Sales 2026 2025 Change Selling, general and administrative expenses as a percentage of Net sales, GAAP 39.0 % 38.6 % 40 Strategic Growth and Productivity Program (0.1 )% — % ERISA litigation matter — % (0.3 )% Selling, general and administrative expenses as a percentage of Net sales, non-GAAP 38.9 % 38.3 % 60 Other (Income) Expense, Net 2026 2025 Other (income) expense, net, GAAP $ 186 $ 13 Strategic Growth and Productivity Program (165 ) — Other (income) expense, net, non-GAAP $ 21 $ 13 Operating Profit 2026 2025 % Change Operating profit, GAAP $ 964 $ 1,076 (10 )% Strategic Growth and Productivity Program 171 — ERISA litigation matter — 15 Operating profit, non-GAAP $ 1,134 $ 1,091 4 % Basis Point Operating Profit Margin 2026 2025 Change Operating profit margin, GAAP 18.1 % 21.9 % (380 ) Strategic Growth and Productivity Program 3.2 % — % ERISA litigation matter — % 0.3 % Operating profit margin, non-GAAP 21.3 % 22.2 % (90 ) Non-Service Related Postretirement Costs 2026 2025 Non-service related postretirement costs, GAAP $ 26 $ 72 Strategic Growth and Productivity Program (5 ) — ERISA litigation matter — (50 ) Non-service related postretirement costs, non-GAAP $ 20 $ 22 Note: The impact of non-GAAP adjustments may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding. Table 6 Continued Colgate-Palmolive Company Non-GAAP Reconciliations For the Three Months Ended March 31, 2026 and 2025 (Dollars in Millions Except Per Share Amounts) (Unaudited) 2026 Income Before Income Taxes Provision For Income Taxes (1) Net Income Including Noncontrolling Interests Less: Income Attributable to Noncontrolling Interests Net Income Attributable To Colgate- Palmolive Company Effective Income Tax Rate (2) Diluted Earnings Per Share As Reported GAAP $ 892 $ 211 $ 681 $ 35 $ 646 23.6 % $ 0.80 Strategic Growth and Productivity Program 176 37 139 1 138 (0.4 )% 0.17 Non-GAAP $ 1,068 $ 248 $ 820 $ 36 $ 784 23.2 % $ 0.97 2025 Income Before Income Taxes Provision For Income Taxes (1) Net Income Including Noncontrolling Interests Less: Income Attributable to Noncontrolling Interests Net Income Attributable To Colgate- Palmolive Company Effective Income Tax Rate (2) Diluted Earnings Per Share As Reported GAAP $ 953 $ 227 $ 726 $ 36 $ 690 23.7 % $ 0.85 ERISA litigation matter 65 12 53 — 53 (0.3 )% 0.06 Non-GAAP $ 1,018 $ 239 $ 779 $ 36 $ 743 23.4 % $ 0.91 The impact of non-GAAP adjustments may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding. Notes: (1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. (2) The impact of non-GAAP items on the Company’s effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income before income taxes and Provision for income taxes. View source version on businesswire.com: https://www.businesswire.com/news/home/20260501892320/en/ Investor Relations: [email protected] Communications: [email protected]

View stock analysis, news, and events for Cresco Labs, Inc.